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ABSTRACT  
Aims: The aim of present study is to develop Paclitaxel nanoparticles for injectable suspension, an anti-neoplastic drug formulation. 
Study design:  Mention the design of the study here. 
Place and Duration of Study: Sagar Institute of Research & Technology- Pharmacy, Ayodhya Bypass Road, Bhopal, between June 2017 and 
June2018. 
Methodology: The Human serum albumin (HSA) is the most abundant plasma protein in the human blood with a half-life of 19 days. It can 
reversibly bind hydrophobic drug substances, transport them in the body and release drugs at cell surface. The formulation is  prepared by 
homogenization at high-pressure of paclitaxel in the presence of human serum albumin into a nanoparticle colloidal suspension. Paclitaxel nano 
particles have been stabilized by human albumin and maintain the average size of 100 nm  
Results: The particle size of the reconstituted solution is checked using the laser diffraction Technique the particle is White to yellow 
lyophilized after reconstitution the particle become homogeneous milky suspension without visible particulates. Reconstitutio n time NMT 25 
minutes 20.45 sec. The assay was performed by HPLC and found to be 90.0% to 110.0% of label. The retention time of Paclitaxel peak obtained 
in sample corresponds to the respective standards obtained from standards the pH NLT 6.00 to NMT 8.00 Particle size NLT 100 nm – NMT 200 
nm. Sterility test was comply as per USP <71>  
Conclusion: The nano-delivery systems could have the potential to be free of Cremophor EL and ethanol, enhance Paclitaxel solubility, improve 
Paclitaxel pharmacokinetic profiles in vivo, decrease its side effects, passively or actively target to tumor sites due to the EPR (Enhanced 
Permeability and Retention) effect and the use of targeting ligands, respectively, nanotechnology is a very active research area in both academic 
and industrial settings. 
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Paclitaxel (PX), isolated from the bark of Pacific Yew (Taxus 
brevifolia), which was first discovered by Mrs. Monroe E. 
Wall and Mansukh C. Wani, is a white crystalline powder 
with the melting point of ~210°C. It is one of the most 
effective chemotherapeutic drugs and is mainly used to treat 
lung, ovarian, and breast cancer, etc. The mechanism of 
action of PX is to promote and stabilize microtubules and 
inhibit late G2 or M phases of cell cycle, thereby causing the 
cell death. The major limitation of PX is its low water 
solubility (~0.4 μg/mL); thus, it is formulated in organic 
solvents of polyoxyethylated castor oil (Cremophor EL) and 
dehydrated ethanol (50/50, v/v) under the trademark 
“Taxol”. However, Cremophor EL is known to cause serious 
side effects, such as hypersensitivity reactions. As a result, 
prolonged infusion time and pretreatments are required. 
Moreover, the presence of Cremophor EL alters the 
pharmacokinetic profile of PX in vivo which was described 
as unpredictable non-linear plasma pharmacokinetics when 
PX was formulated in Cremophor EL. In addition, PX is a 
substrate of P-glycoprotein (P-gp), which actively pumps PX 
out of the cells and induces drug resistance. To overcome 
this problem, several P-gp inhibitors, such as verapamil and 
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PSC 833, were co-administered with Taxol but the results 
were disappointing due to their toxicity and/or alteration of 
PX pharmacokinetics and biodistribution. Nano-delivery 
systems are promising vehicles in drug delivery because 
they improve solubility of hydrophobic drugs, such as PX, 
and generally have low toxicity as well.  
Nanoparticle delivery systems have attracted increasing 
attention in recent years, especially for cancer therapies. As 
an effective chemotherapeutic agent, PX has been 
formulated in various nano-delivery systems which have 
several advantages over the standard-of-care therapy. First, 
the aqueous solubility of PX can be greatly enhanced when it 
is conjugated with water-soluble polymers, or encapsulated 
into lipid-based NPs. Second, they are small in size (several 
to several hundred nanometers in diameter), which enables 
the preferential delivery of PX into the tumor site due to the 
enhanced permeability and retention (EPR) effect. Third, 
they can escape the recognition of reticuloendothelial 
system (RES) in healthy tissues and therefore reduce the 
side effects of the drug. As a consequence, higher maximum 
tolerated doses (MTD) of NPs are realized. It should be noted 
that, in general, the addition of polyethylene glycol (PEG) on 
the surface of NPs is required to avoid RES clearance. Fourth, 
the pharmacokinetic profiles of the drug from NPs is 
improved, for example, increasing the half-life and tumor 
accumulation of PX. Last, but not the least, the surface of PX 
NP systems can be functionalized with active ligands for 
targeting purpose, which in-turn will further increase the 
tumor uptake and decrease the side effects of the drug1-6. 
Paclitaxel is one of the most effective chemotherapeutic 
drugs ever developed and is active against a broad range of 
cancers, such as lung, ovarian, and breast cancers. Due to its 
low water solubility, paclitaxel is formulated in a mixture of 
Cremophor EL and dehydrated ethanol (50:50, v/v) a 
combination known as Taxol. However, Taxol has some 
severe side effects related to Cremophor EL and ethanol. 
Therefore, there is an urgent need for the development of 
alternative Taxol formulations. The encapsulation of 
paclitaxel in biodegradable and nontoxic nano-delivery 
systems can protect the drug from degradation during 
circulation and inturn protect the body from toxic side 
effects of the drug thereby lowering its toxicity, increasing 
its circulation half-life, exhibiting improved pharmacokinetic 
profiles, and demonstrating better patient compliance. Also, 
nanoparticle-based delivery systems can take advantage of 
the enhanced permeability and retention (EPR) effect for 
passive tumor targeting, therefore, they are promising 
carriers to improve the therapeutic index and decrease the 
side effects of paclitaxel. 
Albumin is a versatile natural protein carrier for targeted 
drug delivery. Human serum albumin (HSA) is the most 
abundant plasma protein in the human blood with a half-life 
of 19 days. Albumin has a number of characteristics that 
make it an attractive drug vehicle in oncology. It is a natural 
carrier of endogenous hydrophobic molecules (such as 
vitamins, hormones, and other water-insoluble plasma 
substances), that are bound in a reversible non-covalent 
manner7-9 Moreover albumin seems to help endothelial 
transcytosis of protein-bound and unbound plasma 
constituents principally through binding to a cell-surface, 
60-kDa glycoprotein (gp60) receptor (albondin). gp60 binds 
to caveolin-1 (an intracellular protein) with subsequent 
formation of transcytotic vesicles (caveolae).10-13 Also, 
osteonectin (known as secreted protein acid rich in cysteine 
[SPARC]) has been shown to bind albumin because of a 
sequence homology with gp60. SPARC, as caveolin-1, is often 
present in some neoplasms (breast, lung, and prostate 
cancer), which could explain why albumin is known to 
accumulate in some tumors and thus facilitates intratumor 
accumulation of albumin-bound drugs.7 Albumin-bound 
(nab-)paclitaxel ABI-007 (Abraxane®; Abraxis BioScience 
and AstraZeneca) is another example of an EPR-based 
nanovector application for breast cancer. It represents one 
of the strategies adopted to overcome the solvent-related 
problems of paclitaxel and it has been recently approved by 
the US Food and Drug Administration for pretreated 
metastatic breast cancer patients.ABI-007 is a novel, 
albumin-bound, 130-nm particle formulation of paclitaxel, 
free from any kind of solvent.14-15 It is used as a colloidal 
suspension derived from the lyophilized formulation of 
paclitaxel and human serum albumin diluted in saline 
solution (0.9% NaCl). In detail human serum albumin 
stabilizes the drug particle at an average size of 130 nm 
which prevents any risk of capillary obstruction and does 
not necessitate any particular infusion systems or 
steroid/antihistamine premedication before the infusion.16 
Preclinical studies, conducted in athymic mice with human 
breast cancer, demonstrated that ABI-007 has a higher 
penetration into tumor cells with an increased anti-tumor 
activity, compared with an equal dose of standard 
paclitaxel.16-17 A phase I clinical study by Ibrahim, conducted 
on 19 patients with solid tumors and breast cancer, showed 
a maximum tolerated dose of ABI-007 about 70% higher 
than that of CrEL paclitaxel formulation (300 mg/m2 for an 
every 3 weeks regimen). Dose-limiting toxicities were 
sensory neuropathy, stomatitis, and ocular toxicity 
(superficial keratopathy and blurred vision at a dose of 375 
mg/m2). No patients experienced hypersensitivity reactions. 
ABI-007 was administered intravenously with no 
premedication, in shorter infusion periods (30 minutes vs 3 
hours for polyoxyethylated castor oil-based paclitaxel) and 
with a standard infusion device. Moreover, pharmacokinetic 
parameters showed a linear trend.18 A phase II trial 
confirmed that ABI-007 has important antitumor activity in 
patients with metastatic breast cancer. The overall response 
rate (at a dose of 300 mg/m2 every 3 weeks) was 48% for 
all patients and 64% for patients in first line therapy. Time 
to tumor progression was 26.6 weeks for all patients and 
48.1 weeks for patients with confirmed tumor responses; 
median overall survival was 63.6 weeks. No severe ocular 
events were noted, and other common taxane-associated 
toxicities were less frequent and less severe (eg, 
myelosuppression, peripheral neuropathy, nausea, vomiting, 
fatigue, arthralgia, myalgia, alopecia).19 
In a large international randomized phase III study, 
equitoxic doses of ABI-007 (260 mg/m2) and 
polyoxyethylated castor oil-based paclitaxel (175 mg/m2) 
were compared in 454 patients with metastitic breast 
cancer. ABI-007 was superior to standard paclitaxel for both 
overall response rate (33% vs 19%, respectively; p = 0.001) 
and time to tumor progression (p = 0.006) in all subgroups 
of patients, but mostly for those receiving the drug as fi rst-
line therapy (42% vs 27%, respectively; p = 0.029). Also in 
this trial the incidence of toxicities was significantly lower in 
the ABI-007 group than the polyoxyethylated castor oil-
based paclitaxel group; in particular, grade 4 neutropenia 
was lower (10% vs 21%, respectively; p = 0.001) despite the 
approximately 50% higher dose. On the other hand, grade 3 
sensory neuropathy was more frequent in the ABI-007 
group (10% vs 2%, respectively; p = 0.001), but it was easily 
managed.20 
The authors explained the increased antitumor activity of 
ABI-007 by the higher intratumor paclitaxel concentrations 
(as reported in preclinical studies) and higher dose 
administered.21 Neymann et al demonstrated also that 
weekly dosing of ABI-007 is safe and produces minimum 
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toxic adverse effect with objective antitumor responses in 
patients previously exposed to paclitaxel.21 
EXPERIMENTAL 
Material: 
The active pharmaceutical ingredient, Paclitaxel is 
compendial in USP. The API used for this project was 
manufactured by Teva Czech Industries s.r.o, Czech Republic. 
Chloroform, Ethanol obtained from Merck India Ltd. Human 
Albumin USP were procured from seracare. All chemicals are 
analytical grade (AR). 
Method: 
Nanoparticles Preparation: 
In this study, various parameters crucial in the preparation 
of Pacitaxal-HSA-NPs of sizes 100–200 nm were optimized 
using a high pressure homogenizer. The working of the high 
pressure homogenizer is based on the principal that 
applying a very high pressure (5,000–60,000 psi) to the 
emulsion passed through a homogenization valve breaks the 
emulsion into nano-sized emulsion droplets evaporating the 
organic solvent from the emulsion leads to the formation of 
nanoparticles. 
Paclitaxel was dissolved in part Chloroform – Ethanol (9:1) 
mixture in glass Duran bottle. Collect specified quantity of 
water for injection and cool to 10 ± 2oC in SS 316L 
manufacturing tank. To the above water for injection, add 
batch quantity of 25 % Human albumin solution under 
continuous stirring (slow stirring to avoid foaming) for 10 
minutes. Add the drug solution from step 1 to Albumin 
solution of Step 3 under high shear mixing to form a white 
homogenous emulsion (Primary emulsion). The primary 
emulsion is subjected to high pressure homogenization. The 
homogenized bulk is subjected to immediate solvent 
evaporation by using thin film evaporator. 
The remaining bulk is stored under 2 – 8 °C till further 
processing. Make up the volume to batch size and continue 
the stirring at 200 - 400 RPM for 15 minutes. Warm the bulk 
at 350C–400C and proceed for filtration using 1.00μ glass 
fiber pre-filter immediately proceed for 1st filtration using 
(0.45+0.2μ) Cellulose acetate filter. Maintain the bulk 
temperature between 350C–40° C. Immediately proceeds for 
2nd filtration using (0.45+ 0.2μ) Cellulose acetate filter. The 
bulk is further filled in USP type I moulded glass vials and 
subjected to Lyophilisation. 
Selection of Homogenization Technique: 
Trials were conducted with high shear homogenizer and 
high speed mixer to evaluate its impact on particle size 
distribution and Z average of the final bulk. The stirrer/ 
mixer evaluated were top mounted High shear homogenizer 
(Make: Miccra) against bottom mounted high shear mixer 
(Make: Merck Millipore). Based on the equipment capability, 
the high shear homogenizer was operated at 17000 RPM for 
5 minutes and the bottom mounted high shear mixer was 
operated at 2850 RPM for 30 minutes. Primary emulsion of 
both the batches was analysed for particle size.  
Selection of Processing Temperature for Primary 
Emulsion: 
The drug product contains Albumin, which being a protein is 
highly susceptible to high temperature and gets denatured. 
The drug substance is sensitive to thermal degradation and 
the exposure to higher temperature during processing may 
lead to degradation of the drug product. Thus maintaining of 
temperature during processing is critical. As per the 
proposed process, primary emulsion is subjected to high 
pressure homogenization. High pressure homogenization 
imparts shear and cavitation leading to appreciable increase 
in bulk temperature. The approximate heat rise after 
homogenization is 2 degree/100 bars. Thus the bulk 
temperature is expected to increase by about 25 degree after 
homogenization at about 1300 bar. Hence it was 
recommended to bring the primary emulsion to a 
temperature of 10 ± 2°C before subjecting it to high pressure 
homogenization. This would restrict the bulk from achieving 
higher temperature.  
Organic Solvent Removal: 
The equipment proposed to be used for organic solvent 
removal from the product was thin film evaporator (namely: 
HYVAP). Various trials were conducted during the machine 
installation phase to understand the machine capability and 
the critical and optimum parameters of the process. The 
initial trials taken for identification of critical parameters 
with either water or model solvents (i.e. Tween 80 or 
mixture with water as a feed). 
Drug product or placebo for Paclitaxel protein-bound 
particle for injectable suspension (albumin bound) 
100mg/vial was not used in these trials; however the 
observations of these trials formed the basis for setting the 
critical parameters for the drug product Table 1. 
 
Table 1: Critical evaporation parameter 
Trial Matrix 
Feed rate range evaluated (kg/hr) Jacket temp range evaluated (oC) Pressure (Vacuum) range evaluated (mbar) 
80-100 30-50 20-50 
 
Selection of Filtration Method: 
Terminal sterilization is the preferred method of choice to 
render a sterile product. However, the choice of method of 
sterilization depends on the sensitivity of the raw materials 
used in the formulation and also the finished product dosage 
form. The forced degradation data of Paclitaxel revealed that 
it is sensitive to heat. Also, Human albumin is not stable at 
higher temperature. Furthermore, the finished product is a 
lyophilized product. Hence terminal sterilization is not a 
feasible option. Thus, aseptic filtration and aseptic 
processing was chosen as method of sterilization of 
proposed product. 
For filter compatibility Study PVDF, PES (supplied by 
Millipore, Sartorious) and Cellulose acetate (supplied by 
Sartorius) were evaluated. Materials were soaked in 80 mL 
drug product bulk individually for 16 hours at room 
temperature. Based on the inventory availability at unit, 
PVDF filter manufactured by Millipore, PES and Cellulose 
acetate filter manufactured by Sartorius were evaluated. The 
filter was removed from the bulk after static soaking and the 
bulk was analysed for Assay and degradation products. 
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Evaluation of Bulk Temperature for Filtration: 
The bulk product is proposed to be sterilized by filtration 
through sterilizing grade filters. Hence trials were performed 
to evaluate impact of bulk temperature on throughput and 
filtration recovery of drug substance. The filtration was done 
through 2” Sartobran P filter at 1.5 bar pressure. The bulk 
temperature range evaluated was 20oC -25°C and 35 oC - 40 
oC. Time required to filter predefined volume of drug product 
was evaluated to assess the impact of bulk temperature on 
throughput Table 2. 
 
Table 2: Filtration Temperature 
Time required for 
filtration 
 
Amount filtered Trial at 20 oC – 25 oC Tiral at 35 oC -40 oC 
30ml 9 sec 7 sec 
35ml 145 sec 65 sec 
40ml 173 sec 64 sec 
 
Cycle Development: 
Freezing: Based on the glass transition temperature, the 
product was loaded onto precooled shelves, maintained at 
about 20°C and product being protein in nature, freezing was 
done in a staged manner to a product temperature of -45°C 
as the drug product contains albumin. Freezing was initiated 
at -5°C as an initial preparation stage for freezing at -30°C. 
Freezing was carried out at -30°C for 2 hours so as to have 
controlled nucleation. Later the product was frozen at -45°C 
for 4 hours above the freezing point temperature to ensure 
complete freezing of the product before initiation of primary 
drying. Primary Drying: Following the freezing step, the 
primary drying was performed in staged manner considering 
the low glass transition temperature of the solution as 
below:  
Primary drying was initiated at -45°C (kept for 45 minutes) 
and then at -12°C (kept for 60 minutes) as an initial 
preparation stage (0.12 mbar). A pressure of about 0.12 
mbar, which about 40% of the vapor pressure over ice at -
12°C (0.3082 mbar) was kept to maintain the pressure 
gradient for sublimation. 
Secondary Drying: After completion of the primary drying 
and the shelf temperature was initially ramped to 20°C for 2 
hours and then finally was dried at 35°C for 5 hours to 
achieve lowest possible water content and Degradation 
products. 
The suitability of the lyophilization cycle was evaluated as 
shown in table 3, 
 
Table 3: Lyophilisation Recipe 
S. No. Processing Parameter Time (h:m) Temperature (oC) Vacuum (mbar) 
1.  Precooling/Start Value 00:00 20 Off 
2.  Freezing 00:30 -5 Off 
3.  Freezing 01:30 -5 Off 
4.  Freezing 00:40 -30 Off 
5.  Freezing 02:00 -30 Off 
6.  Freezing 00:30 -45 Off 
7.  Freezing 04:00 -45 Off 
8.  Sublimation 00:30 -45 Off 
9.  Sublimation 00:30 -45 0.120 
10.  Sublimation 01:00 -12 0.120 
11.  Sublimation 25:00 -12 0.120 
12.  Sublimation 00:15 -12 0.120 
13.  Sublimation 37:00 -12 0.120 
14.  Sublimation 00:30 20 0.018 
15.  Sublimation 02:00 20 0.018 
16.  Sublimation 01:00 35 0.018 
17.  Sublimation 05:00 35 0.018 
Total time: 81:55 hrs 
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Particle size, Size Distribution, Zeta Potential and 
Surface Morphology: 
The size, size distribution, and zeta potential of the HSA 
nanoparticles were determined after sonication and after 
HPH with the dynamic light scattering (DLS) method using a 
Malvern Zetasizer NanoZS (Malvern Instruments, 
Worcestershire, UK). In addition, the shape and surface 
morphology of the HSA nanoparticles were characterized 
after sonication and after HPH using a scanning electron 
microscope (SEM) (KYKY-EM3200, KYKY Technology, 
Shanghai, China). In addition, the particles’ resolution was 
shown with transmission electron microscopy (TEM) (CM30 
300 kV, Berlin, Germany). 
Drug-Loading Capacity and Encapsulation-Efficiency 
Assays: 
To determine the concentration of free pacitaxal, one aliquot 
of the HSA–PXT-NPs was ultrafiltered on a glass membrane 
filter and 200 μl of the filtrate was mixed with 800 μl 
acetonitrile, and vortexed for 3 min. An aliquot of the same 
HSA–PXT-NPs (200 μl) was mixed with 800 μl acetonitrile 
and vortexed for 3 min without other process to determine 
the concentration of total pacitaxal. Pacitaxal concentration 
was then measured by high performance liquid 
chromatography (HPLC). A Hypersil ODS-2 C18 reverse 
phase column (5-μm particle size, 250 mm×4.6 mm) 
(Youngling HPLC) was used in the analysis and the mobile 
phase used consisted of 70% (v/v) acetonitrile and 30% 
deionized water as an isocratic system. Flow rate was 1.2 
ml/min. Encapsulation, drug-loading capacity and 
encapsulation efficiency were calculated as follows: 
 
                                (Eq. 1) 
                                       (Eq. 2) 
                                       (Eq. 3)  
 
RESULTS AND DISCUSSIONS 
Description after Reconstitution Solution and 
Reconstitution time 
The lyophilized drug product is dissolved in 10ml water for 
injection for reconstitution. The water for injection should 
be flushed into the vial from the side of the glass wall. The 
vial is vigorously shaken to reconstitute the solution. The 
approx. time required is around 20 minutes. 
Particle Size 
The primary emulsion was further processed with high 
pressure homogenization and solvent evaporation to get the 
final bulk. Final bulk was again evaluated for Particle size 
distribution and Polydispersity index. The result was show 
in table 3 . The particle size of the reconstituted solution is 
checked using the laser diffraction technique (Fig.1).
 
Table 3: Particle size measurement 
Mixer and RPM PSD (nm) of final bulk 
 D10 D50 D75 D90 
Higher Shear Mixer at 2800 RPM 155 247 322 414 
High Shear homogeniser at 17000 RPM 155 249 327 409 
 
 
Figure1: Size distribution of nanoparticles preparation which shows that the particle diameters of both methods could 
be adjusted between 100 and 200 nm 
 
Drug-Loading Capacity and Encapsulation-Efficiency 
Assays 
To determine the concentration of free pacitaxal, A Hypersil 
ODS-2 C18 reverse phase column (5-μm particle size, 250 
mm×4.6 mm) (Youngling HPLC ) was used in the analysis 
and the mobile phase used consisted of 70% (v/v) 
acetonitrile and 30% deionized water as an isocratic system. 
Flow rate was 1.2 ml/min. the Rt found to be 5.1 min fig 2 
and fig 3,   which are near to stander drug.  Encapsulation, 
drug-loading capacity was found to be 98% w/w-99% w/w.  
By using HPLC method, the active drug content in the 
product is obtained. 
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Figure 2: Chromatogram of Standard 
 
Figure 3: Chromatogram of sample solution 
 
The description of nanoparticles of Paclitaxel before and 
after reconstitution and reconstitution time given in Table 4.  
The average size and size distribution for each preparation 
was the results are given in table 4. The suspensions of 
nanoparticles (as initially formulated in water for injection) 
remained homogeneous and stable for 3–5 days before 
showing significant aggregation. The nanoparticles also 
appear to suspend in an aqueous environment as individual 
particles with a spherical shape. The mean percent yield was 
found to be near 100% with a low of 98.9 (PTX) to high of 
99.7 (blank). The drug loading efficiency and encapsulation 
efficiency was also near 100% similar to the percent yield.
 
Table 4: Test Results  
Test Specification Results 
Description White to yellow lyophilized cake or powder Complies 
Description after reconstitution Homogeneous milky suspension without visible 
particulates 
White milk suspension. 
Reconstitution time  NMT 25 minutes 20.45 sec. 
Identification By HPLC The retention time of Paclitaxel peak obtained in 
sample corresponds to the respective standards obtained 
from standards 
Meet the requirement 
pH  NLT 6.00 to NMT 8.00 7.16 
Water content  NMT 3.00 % w/w 1.8 % 
Particle size  NLT 100 nm – NMT 200 nm Meet the requirement 
Assay of Paclitaxel (%) Between 90.0% to 110.0% of label claim of Paclitaxel 98.9 % w/w 
Free Paclitaxel (%)  NMT 10% 2.0 % 
Sterility  Should comply as per USP <71> Not applicable. 
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CONCLUSION 
Paclitaxel is one of the most effective anticancer drugs ever 
developed. It is active against a broad range of cancers. 
However, the current Taxol formulations have issues related 
to the use of Cremophor EL and ethanol. Since nano-delivery 
systems could have the potential to be free of Cremophor EL 
and ethanol, enhance Paclitaxel solubility, improve Paclitaxel 
pharmacokinetic profiles in vivo, decrease its side effects, 
passively or actively target to tumor sites due to the EPR 
(Enhanced Permeability and Retention) effect and the use of 
targeting ligands, respectively, nanotechnology is a very 
active research area in both academic and industrial 
settings. The preliminary evaluation of this nano technology 
evolved that the drug product is stable and further can be 
evaluation for exhibit batches.  
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